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ABSTRACT	
It	is	debated	if	acromegalic	patients	have	an	increased	risk	to	develop	malignancies.	
The	aim	of	the	present	study	was	to	assess	the	standardized	incidence	ratios	(SIRs)	of	different	types	of	
cancer	in	acromegaly	on	a	large	series	of	acromegalic	patients	managed	in	the	somatostatin	analogs	era.	
It	was	evaluated	the	incidence	of	cancer	in	an	Italian	nationwide	multicenter	cohort	study	of	1512	
acromegalic	patients,	624	men	and	888	women,	mean	age	at	diagnosis	45	+/-	13	years,	followed–up	for	a	
mean	of	10	years	(12573	person-years)	in	respect	to	the	general	Italian	population.	
Cancer	was	diagnosed	at	124	patients,	72	women	and	52	men.	The	SIRs	for	all	cancers	was	significantly	
increased	compared	to	the	general	Italian	population	(expected:	88,	SIR	1.41;	95%CI,	1.18-1.68,	p<0.001).	In	
the	whole	series,	we	found	a	significantly	increased	incidence	of	colorectal	cancer	(SIR	1.67;	95%	CI,1.07-
2.58,	p=0.022),	kidney	cancer	(SIR	2.87;	95%	CI	1.55-5.34,	p<0.001)	and	thyroid	cancer	(SIR	3.99;	95%	CI,	
2.32-6.87,	p<0.001).	The	exclusion	of	11	cancers	occurring	before	diagnosis	of	acromegaly	(all	in	women)	
did	not	change	remarkably	the	study	outcome.	In	multivariate	analysis,	the	factors	significantly	associated	
with	an	increased	risk	of	malignancy	were	age	and	family	history	of	cancer,	with	a	non-significant	trend	for	
the	estimated	duration	of	acromegaly	before	diagnosis.	
In	conclusion	we	found	evidence	that	acromegaly	in	Italy	is	associated	with	a	moderate	increase	in	cancer	
risk.	
INTRODUCTION	
	
Acromegaly	 is	an	uncommon	disease	 sustained	by	hypersecretion	of	GH	and	 IGF-I	and	 is	associated	with	
remarkable	complications	that	may	reduce	life	expectancy	of	these	patients	(Melmed	2009,	Katznelson	et	
al.	2014).	However,	the	effective	control	of	GH	and	IGF-I	excess	is	able	to	reduce	considerably	the	burden	
of	disease.	Recent	population-based	studies	have	showed	that	acromegalic	patients	have	 lower	standard	
mortality	ratios	than	previously	reported	(Sherlock	et	al.	2010),	 reflecting	 improved	treatment	modalities	
that	 became	 available	 in	 recent	 years,	 such	 as	 somatostatin-receptor	 ligands	 	 (SRL)	 and	 pegvisomant	
(Bogazzi	 et	 al.	2013,	 Biermasz	 2014,	Mercado	 et	 al.	2014)	 The	 impact	 of	 acromegaly	 on	 life	 expectancy	
comes	mainly	through	cardiovascular	and	cerebrovascular	events,	since	diabetes	mellitus	and	hypertension	
are	 frequent	 complications	 of	 GH	 and	 IGF-I	 excess	 (Melmed	 2001)	 Recently,	 we	 did	 a	 large-scale	
epidemiological	analysis	on	1512	acromegalic	 Italian	patients	and	 found	that	vascular	disease	and	cancer	
were	the	main	causes	of	death.	Mortality	was	higher	in	patients	with	persistently	active	disease,	and	IGF-I	
levels	 at	 diagnosis,	 GH	 at	 the	 last	 follow-up,	 cancer,	 and	 pituitary	 radiotherapy	 were	 independent	
predictors	of	mortality	(Arosio	et	al.	2012).	
That	 acromegaly	may	 cause	 cancer,	 and	 that	mortality	 due	 to	 cancer	 contributes	 to	 shorten	 survival	 of	
patients	with	acromegaly,	remains	an	unsolved	issue	(Melmed	2001,	Loeper	&	Ezzat	2008,	Boguszewski	&	
Ayuk	2016).	A	wealth	of	preclinical	data	supports	the	view	that	the	GH-IGF	system	plays	an	important	role	
in	 cancer	 development	 and	 progression	 (Loeper	 &	 Ezzat	 2008,	 Pollak	 2008,	 Weroha	 &	 Haluska	 2012,	
Brahmkhatri	et	 al.	2015).	Moreover,	 in	 human	 studies	 there	 is	 convincing	 evidence	 that	 circulating	 IGF-I	
concentrations	at	the	higher	limit	of	the	normal	range	are	linked	with	an	increased	risk	of	several	types	of	
cancers,	 although	 the	 excess	 risk	 seems	moderate	 (Renehan	 et	 al.	2004,	 Clayton	 et	 al.	2011).	 Despite	 a	
sound	 rationale,	 studies	 that	 addressed	 the	 association	 between	 acromegaly	 and	 cancer	 produced	
controversial	 results,	 partly	 due	 to	 the	 different	 methodological	 approaches	 used	 (case-control	 and	
population-based	design)	(Loeper	&	Ezzat	2008,	Ayuk	&	Boguszewski	2016).	Moreover,	it	is	plainly	evident	
that	most	studies	did	not	have	the	statistical	power	to	demonstrate	a	moderate	excess	risk	of	cancer,	as	
expected	 from	the	outcome	of	 studies	 in	 the	general	population	and	case-control	 studies	on	acromegaly	
(Figure	1).	
A	 recent	 meta-analysis	 of	 case-control	 studies	 employing	 colonoscopy	 showed	 that	 acromegaly	 is	
associated	with	an	increased	risk	of	colon	neoplasms,	both	colon	adenomas,	a	premalignant	condition	that	
may	lead	to	overt	cancer,	and	colon	cancers.		Results	were	consistent	among	the	different	studies	with	no	
significant	 heterogeneity	 and	 showed	 an	 overall	 excess	 risk	 of	 about	 two	 times	 (Rokkas	 et	 al.	 2008).	
Another	meta-analysis	of	case-control	studies	focusing	on	thyroid	cancer	showed	an	increased	risk	of	both	
nodular	 thyroid	 disease	 and	 thyroid	 cancer	 in	 acromegaly,	 and	 again	 results	 were	 quite	 homogeneous	
across	studies,	although	with	less	precise	estimate	due	to	the	low	number	of	events	(Wolinski	et	al.	2014).		
Population-based	studies	addressing	cancer	 incidence	 in	acromegaly	produced	controversial	 findings	 that	
may	be	likely	explained	by	difference	in	methodology	and	variable	sample	size	(Table	1).	Also	population-
based	studies	addressing	whether	cancer	mortality	may	contribute	to	overall	mortality	of	acromegaly	came	
to	mixed	conclusions,	with	some	studies	showing	an	association	while	others	did	not	(Table	2).	However,	it	
has	 been	 already	 argued	 that	 studies	 focusing	 on	 mortality	 are	 less	 helpful	 in	 answering	 the	 question	
whether	 acromegaly	 is	 associated	with	 cancer	 because	 the	 prevalent	 cardiovascular	mortality	may	 have	
obscured	 cancer	mortality.	 In	 the	 reported	 series,	 the	median	age	at	death	was	 less	 than	60	 years,	 thus	
most	patients	died	before	they	could	develop	clinically	evident	cancer	(Loeper	&	Ezzat	2008,	Boguszewski	&	
Ayuk	2016).	
The	aim	of	 the	present	 study	was	 to	assess	 the	 standardized	 incidence	 ratios	 (SIRs)	of	different	 types	of	
cancer	 in	 acromegaly	 in	 a	 nationwide	multicenter	 cohort	 study	 in	 Italy	 on	 a	 large	 series	 of	 acromegalic	
patients	who	have	been	treated	in	the	SRL	era.		
	
	
MATERIALS	AND	METHODS	
Subjects	
We	 have	 evaluated	 the	 prevalence	 of	 neoplasia	 from	 an	 Italian	 series	 of	 1512	 patients	 who	 were	
proactively	 followed	 in	 24	 tertiary	 referral	 centers	 in	 Italy.	Patient	 characteristics	 are	 given	 in	 Table	 3.	
Inclusion	 criteria	were	 age	at	diagnosis	 >18	 years	 and	diagnosis	 of	 acromegaly	made	between	1	 January	
1980	and	31	December	2002	according	to	standard	biochemical	criteria	at	the	time	of	enrollment,	with	at	
least	1-year	follow-up	after	diagnosis.	The	mean	follow-up	time	from	diagnosis	to	the	end	of	the	study	was	
120	months	(median:	90	months;	interquartile	range	[IQR]:	42–170	months).	Follow-up	was	closed	in	2011.	
Data	 were	 collected	 retrospectively	 by	 local	 investigators	 in	 a	 computerized	 dataform	 developed	 using	
Access	2000	software	(Microsoft	Corporation	1999)	and	approved	by	all	participants.	All	patients	gave	their	
informed	consent	to	the	collection	of	data	according	to	the	 local	ethic	committee	 indications.	Briefly,	we	
collected	for	each	patients:	demographics,	estimated	date	of	appearance	of	typical	acromegalic	signs,	GH	
and	IGF-I	 levels	at	diagnosis	and	 last	follow-up,	novel	diagnosis	of	malignancies	during	follow-up,	data	on	
family	 history	 of	 cancer,	 smoking,	 drinking,	 participation	 in	 oncology	 screening	 programs.	 For	 further	
details	on	data	capture	and	assessment	see	Arosio	et	al.	(Arosio	et	al.	2012).		
	
Statistical	analysis	
Cancer	 registrations	 were	 coded	 using	 the	 International	 Classification	 of	 Diseases	 ICD-9,	 and	 data	 were	
compared	to	the	general	Italian	population	using	the	cancer	registry	AIRTUM	(Associazione	Italiana	Registri	
Tumori,	www.registri-tumori.it).	The	expected	number	of	cancers	was	calculated	by	multiplying	the	number	
of	 person-years	 by	 the	 appropriate	 national,	 gender-,	 age-,	 calendar	 year-,	 and	 site-specific	 cancer	
incidence	 rate	 for	 each	 five-year	 age	 group	 and	 calendar	 year	 of	 observation.	 Risks	 of	 cancer	 were	
estimated	 by	 computing	 the	 SIRs,	 defined	 as	 the	 observed	 to	 expected	 number	 of	 cancers	 for	 all	
acromegaly	patients	combined,	and	by	gender,	age,	and	years	of	follow-up.	The	95%	confidence	intervals	
(CI)	were	computed	assuming	that	the	observed	number	follows	a	Poisson	distribution	(Liddell	1984).	
Descriptive	 statistics	 were	 worked	 out.	 Continuous	 data	 were	 presented	 as	 medians	 and	 interquartile	
ranges,	or	means	and	standard	deviations.	Discrete	data	are	given	as	counts	and	percentages.	Chi-square	
test	was	performed	to	compare	categorical	data	between	groups	and	the	Mann-Whitney	U	test	was	used	
to	compare	continuous	data.	Levels	of	significance	were	set	at	p<0.05.	
The	 individual	 effect	 of	 patient	 and	 clinical	 variables	 on	 the	 risk	 of	 cancer	 was	 evaluated	 by	 a	 logistic	
regression	model	and	a	univariate	estimate	of	the	Odds	Ratios	(OR)	were	presented	along	with	their	95%	
confidence	 intervals	 (CI).	 A	 multivariable	 model	 was	 then	 considered.	 Variables	 were	 entered	 into	 the	
model	 following	 a	 variable	 selection	 strategy,	 which	 was	 based	 on	 clinical	 judgement	 and	 statistical	
selection	 procedures.	 Model	 fit	 was	 considered	 as	 significantly	 improved	 on	 the	 basis	 of	 the	 Akaike	
Information	Criterion	(AIC)	applied	backwards	for	each	model	(i.e.	starting	from	a	model	with	all	relevant	
variables,	 eliminating	 those	 that	were	not	 significant),	 at	 a	 significance	 level	 of	 0.05.	 Interactions	 among	
variables	were	assessed	by	the	Wald’s	test.		
	RESULTS	
	
Cancer	incidence	
We	found	124	patients	with	diagnosis	of	cancer	in	our	study	cohort	of	1512	acromegalic	followed-up	for	a	
mean	 period	 of	 10	 years	 (12573	 person-years).	 Fourteen	 patients	 had	 multiple	 cancers.	 Eleven	 subject	
registrations	occurred	before	the	date	of	diagnosis	of	acromegaly	(8	breast,	2	colorectal,	1	uterus	cancers)	
but	were	 included	 in	 the	 analysis,	 since	 diagnosis	 of	 cancer	 preceded	 that	 of	 acromegaly	 of	 less	 than	 5	
years,	 which	 is	 within	 the	 time	 lag	 occurring	 between	 onset	 and	 clinical	 diagnosis	 of	 acromegaly	 in	 our	
cohort	 (Arosio	et	al.	2012).	Raw	data	of	 observed	malignancies	 are	 given	 in	 supplemental	 table	 1.	 In	 a	
separate	 analysis,	 we	 restricted	 SIR	 calculation	 to	 the	 malignancies	 observed	 only	 after	 the	 clinical	
diagnosis	of	acromegaly.	
Overall,	SIR	for	all	cancers	was	increased	compared	to	the	general	Italian	population	(SIR	1.41;	95%CI,	1.18-
1.68,	p<0.001).	 In	 the	whole	series,	we	 found	a	significantly	 increased	 incidence	of	colorectal	cancer	 (SIR	
1.67;	95%	CI,	1.07-2.58,	p=0.022),	kidney	cancer	(SIR	2.87;	95%	CI	1.55-5.34,	p<0.001)	and	thyroid	cancer	
(SIR	3.99;	 95%	CI,	 2.32-6.87,	p<0.001).	We	assessed	 the	SIRs	of	different	 cancer	 types	 in	 the	 female	and	
male	 gender,	 respectively	 (Table	 4).	 In	 female	 patients,	 incidence	 of	 all	malignancies	was	 increased	 (SIR	
1.51;	 95%	 CI,	 1.20-1.91,	 p<0.001),	 as	 it	 was	 incidence	 of	 thyroid	 cancer,	 colorectal	 cancer,	 and	 breast	
cancer.	In	male	patients,	incidence	of	all	malignancies	was	increased	(SIR	1.29;	95%	CI,	1.0-1.7,	p=0.06),	as	it	
was	incidence	of	thyroid	cancer,	kidney	cancer,	and	colorectal	cancer.		
The	analysis	of	 the	malignancies	observed	only	after	 the	clinical	diagnosis	of	acromegaly	confirmed	an	
increased	 SIR	 for	 all	 cancer	 in	 the	 overall	 population	 (SIR	 1.28;	 95%CI,	 1.07-1.55,	 p<0.007).	 All	 the	
prevalent	malignancies	were	observed	in	female	patients;	however,	the	incidence	of	all	malignancies	was	
still	increased	(SIR	1.28;	95%CI,	1.00-1.65,	p<0.05)	while	the	incidence	of	breast	cancer	(SIR	0.83;	95%	CI,	
0.50-1.41,	p=NS)	and	 colorectal	 cancer	 (SIR	1.55;	95%	CI,	 0.84-2.89,	p=NS)	were	not	different	 from	 the	
general	female	population.	
A	comparable	number	of	patients	with	or	without	cancer	were	submitted	to	proactive	oncologic	screening	
as	part	of	their	management	(65%	in	patients	with	cancer	vs.	60%	in	patients	without	cancer).		
Predictive	 factors	 of	 cancer	 were	 analyzed	 in	 univariate	 analysis	 (age,	 gender,	 duration	 of	 acromegaly	
before	diagnosis,	presence	of	diabetes,	active	disease	at	last	follow-up,	GH/IGF-I	at	baseline	and	last	follow-
up,	pituitary	radiotherapy,	family	history	of	cancer).	Factors	significantly	associated	with	an	increased	risk	
of	cancer	were	age,	 family	history	of	cancer,	disease	duration	before	diagnosis,	presence	of	diabetes	and	
previous	pituitary	 radiotherapy.	Pertinently,	we	 observed	 only	 3	 cases	 of	 brain	 cancer.	 In	multivariable	
analysis,	 factors	 significantly	 associated	with	 an	 increased	 risk	 of	 cancer	 were	 age	 and	 family	 history	 of	
cancer,	while	there	was	a	non-significant	trend	for	duration	of	acromegaly	(Table	5).	
	DISCUSSION	
	
Whether	 acromegaly	 is	 associated	 with	 increased	 risk	 of	 cancer	 remains	 an	 endless	 debate.	 In	 general,	
case-control	 studies	 focusing	 on	 a	 specific	 tumor	 type	 produced	 more	 homogeneous	 figures,	 as	
demonstrated	 by	 a	 meta-analysis	 of	 colonoscopy-based	 studies	 (Rokkas	 et	 al.	 2008).	 Since	 case-control	
studies	may	 lead	 to	 overestimation	 of	 risk	 due	 to	 ascertainment	 bias	 and	 problems	 related	 to	matching	
with	specific	patient	groups,	the	“well-worried”	bias,	 it	has	been	suggested	that	population-based	studies	
are	more	appropriate	for	assessing	cancer	risk	(Renehan	&	Brennan	2008).		
However,	 population-based	 studies	 produced	 discrepant	 data	 for	 a	 number	 of	 reasons.	 First,	 due	 to	 the	
rarity	of	acromegaly	only	nationwide	surveys	may	have	adequate	statistical	power.	Second,	coverage	and	
accuracy	of	national	cancer	registries,	as	well	as	duration	and	completeness	of	 follow-up,	are	keys	 for	an	
adequate	 comparison	with	 the	 general	 population.	 Third,	 the	 retrospective	nature	of	 these	 studies	 is	 an	
obvious	 limitation,	particularly	when	considering	that	some	studies	date	back	to	the	sixties	 (Wright	et	al.	
1970,	 Alexander	 et	 al.	 1980),	 when	 treatment	 of	 acromegaly	 was	 far	 less	 effective.	 As	 a	 consequence,	
patients	with	uncontrolled	acromegaly	may	have	died	before	entering	the	age	when	cancer	usually	occurs;	
thus,	 competitive	 cardiovascular	morbidity	may	have	hindered	 cancer	 incidence	 and,	 particularly,	 cancer	
mortality	(Loeper	&	Ezzat	2008,	Boguszewski	&	Ayuk	2016).	
The	 aim	 of	 the	 present	 study	 was	 to	 evaluate	 the	 incidence	 of	 cancer	 in	 a	 series	 of	 1512	 acromegalic	
patients	 followed	up	for	10	years	at	24	tertiary	referral	centers	 in	 Italy.	Most	patients	were	treated	after	
the	 introduction	of	SRL	 in	clinical	practice,	 thus	 representing	a	modern	series.	We	 found	 that	 the	overall	
incidence	 of	 cancer	was	 increased	 compared	 to	 the	 general	 population	with	 a	 SIR	 of	 1.41	 (95%CI,	 1.18-
1.68).	 The	 excess	 risk	 is	 only	 moderate	 and	 this	 may	 explain	 why	 less	 powered	 studies	 produced	
controversial	 findings.	Since	 acromegaly	 is	 usually	 recognized	many	 years	 after	 its	 biological	 onset,	we	
included	 in	 the	 analysis	 the	 malignancies	 diagnosed	 within	 a	 period	 of	 5	 years	 prior	 to	 the	 clinical	
diagnosis	of	acromegaly,	to	account	for	the	long	period	of	exposure	to	excess	GH	and	IGF-I	preceding	the	
diagnosis.	Even	if	malignancies	detected	during	this	time	span	are	considered	formally	as	prevalent,	they	
occur	 under	 the	 influence	of	 hormone	excess	 that	 is	 present	 albeit	 undiagnosed.	 Pertinently,	 a	 recent	
survey	 in	 Denmark	 identified	 increased	morbidity	 over	 the	 3	 years	 preceding	 diagnosis	 of	 acromegaly	
(Dal	 et	 al.,	 2016).	However,	we	also	did	a	 separate	analysis	 including	only	 the	malignancies	diagnosed	
after	the	clinical	diagnosis	of	acromegaly	to	provide	a	more	conservative	estimate	of	the	risk.	The	results	
of	this	analysis	overall	confirmed	an	excess	cancer	risk	with	the	exception	of	breast	cancer.	
Only	 three	 studies	 in	 the	 literature	 have	 a	 size	 comparable	 to	 the	 present	 one,	 but	 only	 two	 were	
nationwide	surveys.	Ron	et	al.	(Ron	et	al.	1991)	analyzed	a	cohort	of	1041	male	inpatients	with	acromegaly	
in	 the	 US	 and	 found	 an	 increased	 incidence	 compared	 to	 non-acromegalic	 hospitalized	 patients,	 who	
served	as	controls	(SIR,	1.6;	95%	CI,	1.3-1.9).	This	increased	risk	was	mainly	attributable	to	gastrointestinal	
cancers,	 in	 particular	 colon	 cancer.	 However,	 the	 study	may	 be	 criticized	 for	 the	 inclusion	 of	 only	male	
patients	admitted	to	hospital	and	for	not	having	used	tumor	 incidence	rates	of	the	general	population	as	
reference	(Loeper	&	Ezzat	2008).	Orme	et	al.	(Orme	et	al.	1998)	made	a	large	epidemiological	study	in	the	
UK,	analyzing	a	cohort	of	1239	subjects	with	acromegaly,	and	found	that	the	risk	for	all	malignancies	was	
reduced	 compared	 to	 the	 general	 population	 (SIR,	 0.76;	 95%	 CI,	 0.60-0.95),	 although	 there	 was	 a	 non-
significant	 increase	 in	 the	 incidence	 of	 colon	 cancer	 (SIR,	 1.68;	 P=0.06).	 However,	 they	 excluded	
approximately	 17%	 of	 cancer	 registrations	 that	 occurred	 before	 the	 diagnosis	 of	 acromegaly.	 Since	 the	
diagnosis	of	acromegaly	is	usually	made	years	after	its	biological	onset,	excluding	such	cases	may	cause	an	
underestimation	of	the	phenomenon	(Loeper	&	Ezzat	2008,	Boguszewski	&	Ayuk	2016).	Baris	et	al.	(Baris	et	
al.	2002)	made	an	epidemiological	study	in	Sweden	and	Denmark,	analyzing	a	cohort	of	1634	patients,	and	
found	an	increased	risk	for	all	malignancies	(SIR,	1.5;	95%	CI,	1.3-1.8),	in	particular	of	the	digestive	tract.	
More	recently,	three	smaller	studies	have	been	published	that	provided	controversial	results.	Kauppinen-
Makelin	et	al.	 (Kauppinen-Makelin	et	al.	2005),	 in	a	nation-wide	survey	 in	Finland,	analyzed	334	patients	
and	found	an	increased	cancer	incidence	(SIR,	1.5;	95%	CI,	1.1-1.9).	Due	to	the	low	number	of	events,	it	was	
impossible	to	make	stratification	per	cancer	type,	but	colon	and	thyroid	cancer	were	the	most	frequently	
observed.	Petroff	et	al.	 (Petroff	et	al.	2015)	analyzed	446	patients	 from	the	German	Acromegaly	Registry	
and	found	that	cancer	incidence	was	non-significantly	lower	than	the	general	population	(SIR,	0.75;	95%	CI,	
0.55-1.00).	They	found	a	two	times	higher	incidence	of	thyroid	cancer	in	acromegalic	patients	that	was	not	
significant	due	to	the	low	number	of	events.	However,	the	study	has	limits	in	representing	only	a	sample	of	
the	German	Acromegaly	Registry	and	in	the	methodology	used	to	ascertain	cancer	registration,	which	was	
not	 always	 based	 on	 referring	 to	medical	 records	 but	 included	 also	 phone	 interview.	Moreover,	 16%	 of	
patients	 were	 lost	 to	 follow-up.	 Cheng	 et	 al.	 (Cheng	 et	 al.	 2015)	 reported	 on	 408	 acromegalic	 patients	
followed	at	3	 referral	 centers	 in	Canada	and	 found	 that	 cancer	 incidence	was	higher	 than	 in	 the	general	
population	(OR,	2.87;	95%	CI,	1.57-5.25).	In	this	cohort,	diabetes	was	associated	to	the	risk	of	malignancy.	
The	 present	 study	 has	 strengths	 in	 the	 large	 population	 sample	 and	 long	 follow-up	 with	 all	 cancer	
registrations	 confirmed	 by	 the	 physicians	 who	 proactively	managed	 the	 patients.	 Our	 study	 cohort	 was	
collected	in	many	referral	centers;	thus	it	is	representative	of	the	acromegalic	population	in	Italy.	It	is	also	
representative	of	a	cohort	treated	in	a	modern	way	as	demonstrated	by	the	overall	mortality	data	(Arosio	
et	 al.	 2012)	 in	 a	 range	 comparable	 to	 those	 observed	 in	 more	 recent	 studies	 (Katznelson	 et	 al.	 2014,	
Sherlock	et	al.	2010,	Mercado	et	al.	2014).	Our	findings	on	cancer	incidence	are	in	close	agreement	with	the	
nationwide	survey	in	Finland	(Kauppinen-Makelin	et	al.	2005)	that	was	done	in	the	same	time	period	(SIR	of	
the	 present	 study,	 1.41;	 SIR	 of	 the	 Finnish	 study,	 1.5).	 The	 outcome	of	 the	German	 study	 (Petroff	et	 al.	
2015),	which	 is	 also	 a	 contemporary	 series,	 is	 at	 variance	 but	 the	 above-mentioned	differences	 in	 study	
methodology	may	explain	the	discrepancy.		
Due	 to	 our	 large	 sample	 size,	we	were	 able	 to	 consider	 separately	 cancer	 incidence	 between	 sexes	 and	
make	a	meaningful	stratification	of	different	cancer	types.	Risk	of	cancer	was	higher	 in	women	(SIR	1.51;	
95%	CI,	 1.20-1.91)	 than	 in	men	 (SIR	 1.29;	 95%	CI,	 1.0-1.7),	 and	 this	may	be	 attributable	 to	 the	 fact	 that	
women	were	older	 in	our	series.	Cancers	 found	 to	be	more	consistently	 increased	were	 thyroid	 cancer,	
kidney	cancer	and	colorectal	cancer.	These	findings	are	consistent	with	abundant	evidence	linking	the	IGF	
system	with	development	and	progression	of	all	these	cancers	(Loeper	&	Ezzat	2008,	Pollak	2008,	Weroha	
&	Haluska	2012,	Brahmkhatri	et	al.	2015,	Renehan	et	al.	2004,	Clayton	et	al.	2011,	Giovannucci	et	al.	2000,	
Pekic	&	Popovic	2013).		
The	increased	risk	of	colon	neoplasia	in	acromegaly	is	the	most	widely	agreed;	thus,	the	Endocrine	Society	
Guidelines	 suggested	 incorporating	 colonoscopy	 at	 diagnosis	 in	 the	 management	 of	 acromegaly-related	
comorbidities	 (Katznelson	 et	 al.	 2014).	 Higher	 risk	 of	 breast	 cancer	 has	 been	 reported	 in	 an	 old	 study	
(Nabarro	 1987),	 while	 recent	 studies	 found	 only	 non-significant	 increase	 in	 risk	 (Baris	 et	 al.	 2002,	
Kauppinen-Makelin	 et	 al.	2005,	Petroff	et	al.	 2015).	However,	 assessing	 the	prevalence	 in	 acromegaly	of	
breast	cancer	is	particularly	challenging	since	it	may	be	looked	at	only	in	women,	thus	substantially	halving	
the	sample	size.	In	addition,	IGF-I	excess	could	have	different	effects	depending	on	the	menopausal	state,	
and	on	the	levels	of	other	sex	and	growth	hormones,	further	 increasing	complexity	(Renehan	et	al.	2004,	
Tworoger	et	al.	2011).		In	recent	reports,	there	is	increasing	evidence	that	thyroid	cancer	is	more	frequent	
in	 patients	 with	 acromegaly	 than	 in	 control	 groups	 (Wolinski	 et	 al.	 2014).	 A	 recent	 cross-sectional	
prospective	study	 in	Spain	found	that	either	benign	nodular	thyroid	disease	or	thyroid	cancer	were	more	
frequent	in	123	patients	with	acromegaly	than	in	50	matched	controls	applying	highly	sensitive	ultrasound	
methodology	 and	 standardized	 use	 of	 FNA	 cytology	 (Reverter	 et	 al.	 2014).	 Conversely,	 the	 association	
between	acromegaly	and	kidney	cancer	has	been	less	frequently	reported	(Cheung	&	Boyages	1997,	Baris	
et	 al.	 2002,	 Kauppinen-Makelin	 et	 al.	 2005).	 Interestingly,	 expression	 of	 the	 IGF-I	 receptor	 has	 been	
associated	with	poor	survival	in	patients	with	early-stage	renal	cancer	(Parker	et	al.	2004).	
The	present	study	is	the	first	to	provide	a	multivariate	analysis	aiming	at	identifying	predictors	of	cancer	in	
acromegaly.	 We	 found	 that	 age	 and	 family	 history	 of	 cancer	 were	 significant	 independent	 factors	
associated	 to	 cancer	 risk,	 and	 these	 findings	 are	biologically	 plausible.	Moreover,	 a	 non-significant	 trend	
between	cancer	risk	and	delay	in	acromegaly	diagnosis	was	apparent,	but	it	is	known	that	the	estimate	of	
duration	of	acromegaly	 is	admittedly	 imprecise	and	operator	dependent.	We	did	not	 find	evidence	of	an	
association	between	values	of	GH	and	IGF-I,	or	both,	and	cancer	risk.	Orme	et	al.	(Orme	et	al.	1998)	found	a	
higher	cancer-related	mortality	in	patients	with	elevated	post-treatment	GH	but	no	clear	link	between	GH	
and	 IGF-I	 levels	and	cancer	 incidence	 in	acromegaly	has	been	definitively	proven.	This	does	not	discredit	
the	view	that	GH	and	IGF-I	are	 implicated	 in	cancer	development	 in	acromegaly.	 It	has	to	be	pointed	out	
that	the	hormonal	evaluation	at	diagnosis	or	at	the	last	follow-up	may	give	only	a	poor	estimate	of	patient’s	
exposure	to	GH	and	 IGF-I	 in	the	course	of	a	chronic	disease	such	as	acromegaly.	Moreover,	other	factors	
may	 play	 important	 roles	 in	 determining	 the	 risk	 of	 neoplasia	 in	 acromegaly,	 such	 as	 insulin,	 insulin	
resistance,	 IGF-BP1	 and	 BP3,	 obesity,	 body	 composition	 and	 leptin	 levels	 (Melmed	 2001,	 Boguszewski	&	
Ayuk	2016,	Giovannucci	et	al.	2000,	Pekic	&	Popovic	2013,	Tworoger	et	al.	2011).	In	this	line,	it	is	interesting	
the	finding	of	Cheng	et	al.	(Cheng	et	al.	2015)	that	acromegalic	patients	with	diabetes	had	more	malignant	
tumors	 than	 non-diabetic	 patients.	 In	 our	 cohort,	 diabetes	 was	 associated	 with	 cancer	 risk	 only	 in	
univariate	analysis.		The	alternative	hypothesis	that	cancer	risk	in	acromegaly	is	due	to	common	underlining	
genetic	 factors	 should	 be	 also	 considered	 (Loeper	 &	 Ezzat	 2008,	 Boguszewski	 &	 Ayuk	 2016,	 Renehan	&	
Brennan	2008).		
Limitations	 of	 our	 study	 are	 its	 retrospective	 nature,	 as	 for	 previous	 epidemiological	 studies,	 the	
consequent	 lack	 of	 data	 on	 the	 cumulative	 GH	 exposure,	 that	 has	 been	 recently	 suggested	 as	 a	 very	
important	determinant	of	morbidity	and	mortality	(Varadhan	et	al.	2016),	and	the	fact	that	patients	have	
been	submitted	in	many	centers	to	proactive	oncologic	screening,	since	previous	studies	conducted	in	Italy	
have	 suggested	 an	 association	 between	 acromegaly	 and	 colon	 neoplasia	 (Terzolo	et	 al.	2005)	 or	 thyroid	
cancer	 (Gasperi	 et	 al.	 2002,	 Tita	 et	 al.	 2005).	 However,	 the	 rate	 of	 patients	 who	 underwent	 cancer	
screening	 was	 alike	 between	 patients	 with	 and	without	 cancer;	 thus,	 it	 is	 unlikely	 that	 our	 findings	 are	
explained	by	an	ascertainment	bias.		
In	conclusion,	we	found	evidence	that	acromegaly	is	associated	with	a	moderate	increase	in	cancer	risk	in	a	
nation-wide	survey	in	Italy.		
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FIGURE	LEGENDS	
Figure	1	–	Sample	size	of	the	population-based	studies	on	acromegaly	and	cancer.	
	
	
	
	
	
